Skip to main content
. 2013 Jan 16;8(1):e53624. doi: 10.1371/journal.pone.0053624

Figure 1. Effect of MDS BM microenvironment on BMEC-1 proliferation.

Figure 1

(A) BMEC-1 proliferation curve. To analyze the effect of the BM supernatant fluid from MDS patients and controls on BMEC-1 proliferation, the cell line was incubated with BM supernatant fluid. The cell number was estimated by MTT at two, four or six days. The measurement of absorbance is indicative of the rate of cell proliferation and each value of each patient is the mean of four independent experiments. Each point is the mean of these values ± SEM. The graphics show the increase of proliferation in MDS patients. ANOVA test was used to analyze the overall MDS results at sixth day. The proliferation was 2.4 times higher in MDS than controls (p<0.005). (B) The box plot compares median levels of BMEC-1 proliferation at sixth day in the different subtypes of MDS. Whiskers represent the range. Significant differences between RCMD and the control group (p<0.01), the other low-risk MDS and the control group (p<0.05) and high-risk MDS patients and the controls (p<0.05) were observed by Mann-Whitney test. MDS: myelodysplastic syndrome; BM: bone marrow; BMEC-1: bone marrow endothelial cells; MTT: Thiazolyl Blue Tetrazolium Bromide; SEM: standard error of the mean; RCMD: refractory cytopenia with multilineage dysplasia. (Controls n = 8; MDS n = 14; Low-Risk MDS excluding RCMD n = 6; RCMD n = 4; High-Risk MDS n = 4).